Table 2.

Univariate and Multivariate Analyses of the Prognostic Factors for OS

Variables	Univariate Analysis			Multivariate Analysis
	Hazard Ratio	95% CI	P value	Hazard Ratio	95% CI	P value
Age, years (>45 vs ≤45)	1.029	0.278–3.804	0.996	0.030	0.001–1.017	0.051
Gender (male vs female)	0.728	0.094–5.639	0.761
ECOG-PS (0 vs 1)	5.801	1.798–18.712	0.003*	13.403	1.766–30.171	0.027*
AFP (≥400 vs <400ng/mL)	3.503	0.937–13.099	0.062	2.432	0.509–11.613	0.265
HBsAg (- VS +)	0.804	0.174–3.719	0.780
TBil (umol/L)	1.047	0.991–1.017	0.098
ALB (g/L)	0.908	0.791–1.042	0.169
PT (s)	1.212	0.902–1.627	0.202
Child-Pugh score (5~6 vs 7)	4.927	1.302–18.642	0.019*	5.981	1.208–29.609	0.040*
Cirrhosis (no vs yes)	1.230	0.159–9.534	0.843
Tumor type (primary vs relapse)	0.370	0.115–1.197	0.097	0.069	0.001–4.951	0.220
Portal vein thrombus (no vs I/II vs III/IV)	1.924	1.008–3.671	0.047*	0.147	0.007–3.133	0.219
Extrahepatic metastasis (no vs yes)	1.112	0.353–3.506	0.856	5.159	0.612–43.454	0.131
Previous treatment (first-line vs second-lines vs third-lines or more)	0.334	0.148–0.756	0.008*
Treatment (lenvatinib group vs lenvatinib plus camrelizumab group)	0.625	0.188–2.077	0.443	5.785	0.221–8.998	0.292

Note: *P<0.05.

Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group Performance Status; AFP, α‐fetoprotein; ALB, albumin, PT, prothrombin time.